We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-1.2%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$548M
AUM Growth
-$212M
Cap. Flow
-$139M
Cap. Flow %
-25.42%
Top 10 Hldgs %
37.58%
Holding
232
New
36
Increased
20
Reduced
48
Closed
92

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$11.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.51M
3
UTHR icon
United Therapeutics
UTHR
+$8.13M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.75M
5
ALT icon
Altimmune
ALT
+$5.53M

Top Sells

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$21M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$9.33M
3
SAGE
Sage Therapeutics
SAGE
+$8.38M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.11M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 43.2%
2 Technology 0.14%
3 Consumer Staples 0.03%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLSA
226
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
– –
-77,274
Closed -$762K
GBT
227
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-49,997
Closed -$1.73M
SRRA
228
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-217,915
Closed -$6.98M
PBLA
229
DELISTED
Panbela Therapeutics, Inc. Common Stock
PBLA
– –
-15
Closed -$750K
GNCA
230
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-206,336
Closed -$259K
BHVN
231
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-60,000
Closed -$7.11M
INBX
232
CALL
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-85,800
Closed -$1.91M
6 7 8 9
10

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Ikarian Capital held 232 positions worth $548M, down 28% from $760M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital withdrew a net $139M in Q2 2022, closing 92 positions and reducing 48 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in Esperion Therapeutics worth $13.1M.

  • Ikarian Capital's largest Q2 2022 buy was Esperion Therapeutics: 2,054,602 shares worth $13.1M.
  • Ikarian Capital added most to Alnylam Pharmaceuticals in Q2 2022, an estimated $8.51M increase.
  • Ikarian Capital's biggest Q2 2022 reduction was Adicet Bio, cutting an estimated $5M.
  • Ikarian Capital fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $21M.
  • Ikarian Capital's ten largest holdings make up 38% of its $548M portfolio in Q2 2022.
  • Ikarian Capital opened 36 new positions and closed 92 in Q2 2022.
  • Ikarian Capital's portfolio value fell 28% quarter-over-quarter to $548M.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.